CDKN2B and metabolic syndrome: In addition, results revealed that lncRNA CDKN2B‐AS1 rs1333045T>C was significantly associated with a decreased risk of MetS progression under co‐dominant, dominant, and log‐additive models after adjustment (CT vs. TT: OR = 0.57, 95% CI 0.37–0.88, p = 0.007; CC vs. TT: OR = 0.47, 95% CI 0.26–0.84, p = 0.007, co‐dominant model, CT + CC vs. TT: OR = 0.66, 95% CI 0.39–1.10, p = 0.003, dominant model, and TT vs. TC vs. CC: OR = 0.66, 95% CI 0.50–0.88, p = 0.004, log‐additive model).